Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
about
Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumorsEffect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapyCost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.Current status of publicly available sarcoma cell lines for use in proteomic studies.Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.
P2860
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Cost-effectiveness of 3-years ...... s (GIST) in the United States.
@en
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors
@nl
type
label
Cost-effectiveness of 3-years ...... s (GIST) in the United States.
@en
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors
@nl
prefLabel
Cost-effectiveness of 3-years ...... s (GIST) in the United States.
@en
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors
@nl
P2093
P1476
Cost-effectiveness of 3-years ...... s (GIST) in the United States.
@en
P2093
Anju Parthan
Douglas C A Taylor
John Coombs
Marc Paolantonio
Medha Sasane
Myrlene Sanon
P304
P356
10.3111/13696998.2012.709204
P407
P577
2012-07-19T00:00:00Z